US Patent Issued to Novartis on Oct. 6 for "Crystalline forms of a BTK inhibitor" (Swiss Inventors)

ALEXANDRIA, Va., Oct. 6 -- United States Patent no. 12,751,949, issued on Oct. 6, was assigned to Novartis AG (Basel, Switzerland).

"Crystalline forms of a BTK inhibitor" was invented by Daniela Angst (Basel, Switzerland) and Andreas Kordikowski (Binningen, Switzerland).

According to the abstract* released by the U.S. Patent & Trademark Office: "This application relates to various anhydrous crystalline forms N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide, as well as compositions, method of making and methods of using the same. These crystalline forms are useful in the treatment of diseases and disorders which are typically ameliorated by the inhibition of BTK. Such di...